Progress in breast cancer progression

Breast cancer is the most common cancer among women and the second leading cause of cancer death among women. The prognosis for cancer patients is related to the stage of the tumor. The latter stages are the most deadly as the tumors have become metastatic, meaning they have become mobile and are able to invade other tissues in the body.

Understanding how tumors progress from early to later stages is essential for devising appropriate therapies. Thomas Wirth and colleagues, from Ulm University in Germany, used a breast cancer model system to show that a protein called NF-kB, which works in the cell by turning on a variety of other genes, is involved in tumor progression when its activity in the cell is altered. The authors showed that NF-kB is essential for the initial transition stage called epithelial-mesenchymal transition, which is thought to be important for allowing tumors to be able to invade other tissues.

Using a cell line that would undergo this transition when given a growth factor, the authors showed that when NF-kB activity was blocked, these cells could not undergo the transition. Furthermore, if the NF-kB pathway was over-activated, the cells no longer required the addition of the growth factor to transition, but instead would spontaneously undergo the epithelial-mesenchymal transition. Further, inhibiting NF-kB after transition had already occurred caused these cells to revert back to their original state. To test this in a living model, the authors blocked the NF-kB pathway in nude mice that were injected with breast cancer cells.

Under these conditions, these breast cancer cells were unable become metastatic, unlike those that were injected in nude mice where the NF-kB pathway was not blocked. Taken together, these data provide evidence for an essential role of NF-kB in the induction and maintenance of the transition that cancer cells undergo to become invasive and mark the NF-kB pathway as a potential anti-metastatic

Contact: Laurie Goodman
Journal of Clinical Investigation

Page: 1 2

Related biology news :

1. Progress in probing the mosquitos sense of smell
2. Progress in the genetics of autism
3. Progress on the molecular basis of mental illness in children
4. Progressor chimpanzees could reveal mechanism for resisting AIDS
5. Progress in mental retardation research
6. UCSF Researchers Pinpoint Molecule That Triggers Deadly Progress Of Pulmonary Fibrosis
7. Tracking A Killers Progression
8. Scientists Make Progress Toward Gene Therapy For HIV Infection
9. Long-Term Study Looks At HIV Positive Men With Few Signs Of Disease Progression, 10-18 Years After Seroconversion
10. Scientists Identify Key Protein Involved In Progressive Blindness
11. Cholesterol Lowering Drugs Stall Disease Progression In People With Below-Average Blood Cholesterol Level

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: